Pulmonary Hypertension in Dialysis Patients: A Cross-Sectional Italian Study by Fabbian, Fabio et al.
SAGE-Hindawi Access to Research
International Journal of Nephrology
Volume 2011, Article ID 283475, 4 pages
doi:10.4061/2011/283475
Clinical Study
PulmonaryHypertensionin Dialysis Patients:
A Cross-Sectional Italian Study
FabioFabbian,1 Stefano Cantelli,1 ChristianMolino,1 Marco Pala,1
CarloLonghini,1 andFrancesco Portaluppi2
1Department of Clinical and Experimental Medicine, University Hospital St. Anna, Corso Giovecca 203, 44100 Ferrara, Italy
2Hypertension Unit, University Hospital St. Anna, 44100 Ferrara, Italy
Correspondence should be addressed to Fabio Fabbian, f.fabbian@ospfe.it
Received 31 July 2010; Accepted 26 August 2010
Academic Editor: Mitchell H. Rosner
Copyright © 2011 Fabio Fabbian et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction. Pulmonary hypertension (PHT) is an independent predictor of mortality. The aim of this study was to relate
pulmonary arterial pressure (PAP) to the cardiovascular status of dialysis patients. Methods. 27 peritoneal dialysis (PD) and 29
haemodialysis(HD)patients(60±13years,37males,dialysisvintagewas40±48months)hadPAPmeasuredbyechocardiography.
Clinical and laboratory data of the patients were recorded. Results. PHT (PAP > 35mmHg) was detected in 22 patients (39%; PAP
42 ± 6mmHg) and was diagnosed in 18.5% of PD patients and 58.6% of HD patients (P = .0021). The group of subjects with
PH had higher dialysis vintage (63 ± 60 versus 27 ± 32 months, P = .016), interdialytic weight gain (2.1 ± 1v e r s u s1 .3 ± 0.9Kg,
P = .016), lower diastolic blood pressure (73 ± 12 versus 80 ± 8mmHg, P = .01) and ejection fraction (54 ± 13 versus 60 ± 7%,
P = .021) than the patients with normal PAP. PAP was correlated positively with diastolic left ventricular volume (r = 0.32,
P = .013) and negatively with ejection fraction (r =− 0.54, P<. 0001). PHT was independently associated with dialysis vintage
(OR 1.022, 95% CI 1.002–1.041, P = .029) and diastolic blood pressure (OR 0.861, 95% CI 0.766–0.967, P = .011). Conclusions.
PHT is frequent in dialysis patients, it appears to be a late complication of HD treatment, mainly related to cardiac performance
and cardiovascular disease history.
1.Introduction
Pulmonary hypertension (PHT) is a progressive disorder
complicatingheart,lung,orsystemicdiseases,withincreased
morbidity and mortality regardless of its etiology [1].
Recently it has been found that PHT is a strong independent
predictor of mortality in haemodialysis (HD) patients [2].
In patients with end-stage renal disease (ESRD), PHT has
been recognized to be a frequent condition and it appears to
be independent from cardiovascular disease prevalence [2].
In a recent review, the prevalence of PHT in ESRD patients
was reported to be around 40%–50% [3]. Its frequency has
been reported to be higher in HD patients than in peritoneal
dialysis(PD)onesduetothepresenceofarteriovenousﬁstula
(AVF) [4, 5]. Clinical features associated with PHT in ESRD
are still a matter of debate, therefore, we evaluated clini-
cal characteristics associated with high pulmonary arterial
pressure (PAP) measured by echocardiography in a group of
Italian dialysis patients.
2.SubjectsandMethods
Between January 2007 and June 2007, 56 dialysis patients
underwent PAP measurement by echocardiography (age
60 ± 13 years, dialysis vintage 40 ± 48 months). They
were selected from a population of 127 subjects dialysing
in a single centre because they accepted to undergo
echocardiography. Twenty nine were on HD treatment via
surgically created native AVF and 27 were on PD therapy.
Glomerulonephritis was the commonest cause of uraemia
(n = 23), ischaemic renal disease, cystic disease and
interstitial nephritis were the renal diagnosis in 8 cases,
respectively, 6 patients had diabetic nephropathy whereas
3 had undetermined renal diagnosis. Patients with chronic
obstructive lung disease, chest wall or parenchymal lung
disease, previous pulmonary embolism, collagen vascular
disease, systemic lupus erythematosus were excluded.
The following demographic and clinical data were
derived from clinical records: age, duration of dialysis2 International Journal of Nephrology
treatment, smoking and diabetes history. The increase
in weight during the interdialytic time (interdialytic
weight gain), systolic and diastolic blood pressure (BP)
were averaged from values recorded at the beginning of
dialysis sessions during the month preceding the date
of echocardiography. BP measurements were performed
according to guidelines [6]. Mean dry weight of each subject
was averaged from the values recorded at the end of the
dialysis sessions during the same period. Average levels of
calcium, phosphate, parathyroid hormone (PTH, measured
as intact molecule by radioimmunoassay), haemoglobin,
haematocrit measured at least twice in the study period
were calculated. Weekly dose of erythropoietin and calcium-
phosphate product were also calculated. Ischaemic heart
disease was deﬁned either from history of myocardial
infarction and/or angina associated to ischaemic changes
on electrocardiogram, or by positive results at either
electrocardiographic ergometry, dipyradamole scintigraphy,
or dobutamine echocardiography. History of previous
TIA or stroke deﬁned cerebrovascular disease. History of
claudication, amputation or presence of ischaemic lesions of
lower limb extremities deﬁned peripheral vascular disease.
History of parathyroidectomy was also recorded.
Echocardiography was performed the day after a dialysis
session when the patient had reached the “dry weight”
prescribed by nephrologists on the clinical examination, in
order to avoid clincal evident ﬂuid overload. One expe-
rienced cardiologist performed all examinations using an
Acuson Sequoia, 512 (Mountain View, CA, USA) ultrasound
machine.
Every patient underwent a complete two-dimensional
and Doppler echocardiography study.
Systolic pulmonary artery (PAP) pressure was calculated
using the modiﬁed Bernoulli equation given by: PAP = 4 ×
(tricuspid systolic jet)2 + 10mm Hg (estimated right atrial
pressure) [7]. According to Yigla et al. [2] PHT was deﬁned
as a systolic PAP > 35mmHg. Diastolic left ventricular
volume, ejection fraction, mitral and aortic valve stenosis
or incompetence were also derived from echocardiographic
studies. Local ethics committee approved this observational
study. The study was conducted according to the Declaration
of Helsinky.
3.StatisticalAnalysis
Data are expressed as mean ± standard deviation and as
percentagewhentheparameterwascategorical.Patientswere
investigated dividing PD and HD subjects with and with-
out PHT. Diﬀerence between groups were compared with
Student’s t-test for parametric continuous variables, Mann-
Witney-U test for nonparametric continuous variables. Chi-
square test was applied for estimating the occurrence of
categorical variables. Pearson’s correlation coeﬃcient was
used to test the relationship between PAP and echocar-
diographic parameters. Multiple logistic regression analysis
was performed considering presence/absence of PHT as
dependent variable, whilst all the variables that resulted
statistically diﬀerent in the univariate analysis, were con-
sidered as independent ones. A P value <.05 was used as
Table 1:Datadescribingthe56patientsinwhompulmonaryartery
pressure was evaluated.
Age (year) 60 ± 13
Dialysis vintage (months) 40 ± 48
Dry weight (kg) 68,5 ± 15
Interdialytic weight gain (kg) 1,6 ± 1
Systolic blood pressure (mmHg) 132 ± 20
Diastolic blood pressure (mmHg) 77 ± 11
Calcium (mg/dl) 9 ± 1
Phosphate (mg/dl) 5 ± 1
Calcium-phosphate product (mg2/dl2)4 8 ± 15
PTH (pg/ml) 344 ± 340
Haemoglobin (gr/dl) 11,3 ± 1,4
Haematocrit (%) 35 ± 5
Erythropoietin (IU/week) 7243 ± 8752
Left ventricular Diastolic Volume (ml) 116 ± 33
Ejection Fraction (%) 58 ± 10
PAP (mmHg) 33 ± 8
the thresholds of statistical signiﬁcance. All analyses were
performed using StatView for windows.
4. Results
Characteristics of the 56 patients investigated are summa-
rized in Table 1, 22 of them had PHT (39%), their mean age
was 66 ± 13 years and 37 were males.
Five (18.5%) in the PD group and 17 (58.6%) in the
HD one had PAP > 35mmHg (P = .0021). Clinical and
biochemical data of the 22 patients with PHT (PAP 42 ±
6mmHg) compared with the 34 patients without PH (28 ±
3mmHg) are shown in Tables 2 and 3.T h em e a nd u r a t i o n
of dialysis therapy was signiﬁcantly longer (63 ± 60 versus
27 ± 32 months, P = .0105) and interdialytic weight gain
was higher (2.0 ± 1v e r s u s1 . 3± 0.9Kg, P = .0168) in the
PHT group than in group with normal PAP. On the contrary
diastolic blood pressure (73 ± 12 versus 80 ± 8mmHg, P =
.01)andejectionfraction(54 ±13versus60 ±7%,P = .021)
werelowerinPHTpatientsthaninsubjectswithnormalPAP.
Inthesamegroupwefoundhigherprevalenceofdiabetes(18
versus 3%, P = .05) and mitral incompetence (100 versus
79%, P = .02).
PD patients with PHT had higher prevalence of diabetes
(40 versus 0% P = .0021), aortic incompetence (100 versus
45%, P = .0267), higher systolic blood pressure (154 ±
29 versus 129 ± 13mmHg, P = .0074) and lower ejection
fraction (45 ± 15 versus 62 ± 5%, P = .0003) than those
without PHT. HD patients with PHT had higher prevalence
of smoking history (76 versus 41%, P = .0571) and lower
diastolic blood pressure (69 ± 11 versus 79 ± 8mmHg, P =
.0196) than those without PHT.
PAP was correlated positively with diastolic left ventric-
ular volume (r = 0.32, P = .013) negatively with ejection
fraction (r =− 0.54, P<. 0001).International Journal of Nephrology 3
Table 2: Clinical and laboratory data of patients with and without
pulmonary hypertension.
PAP ≤ 35 PAP > 35 P
(n = 34) (n = 22)
Age (year) 59 ± 14 61 ± 12 ns
Male/Female (n (%)) 22/12 15/7 ns
Diabetes (n (%)) 1 (3%) 4 (18%) 0.05
Smoking history (n (%)) 19 (56%) 17 (77%) ns
Dialysis vintage (months) 27 ± 32 63 ± 60 0.0105
Dry weight (kg) 70 ± 16 65 ± 13 ns
Interdialytic weight gain (kg) 1,3 ± 0,9 2,0 ± 1.0 0.0168
Systolic blood pressure
(mmHg) 132 ± 15 132 ± 27 ns
Diastolic blood pressure
(mmHg) 80 ± 87 3 ± 12 0.0102
Calcium (mg/dl) 8,9 ± 19 ± 1n s
Phosphate (mg/dl) 5,2 ± 1,7 5,2 ± 0,9 ns
Calcium-phosphate product
(mg2/dl2) 48 ± 18 48 ± 10 ns
PTH (pg/ml) 316 ± 313 388 ± 381 ns
Haemoglobin (gr/dl) 11,4 ± 1,5 11 ± 1,4 ns
Haematocrit (%) 36 ± 53 4 ± 5n s
Erythropoietin (IU/week) 5980 ± 7664 9272 ± 10015 ns
Table 3: Cardiovascular condition of patients with and without
pulmonary hypertension.
PAP ≤ 35 PAP > 35 P
(n = 34) (n = 22)
Hypertension history (n (%)) 29 (85%) 17 (77%) ns
Ischaemic heart disease (n (%)) 11 (32%) 10 (45%) ns
Cerebrovascular disease (n (%)) 8 (24%) 5 (23%) ns
Peripheral vascular disease (n (%)) 11 (32%) 6 (27%) ns
Parathyroidectomy history (n (%)) 4 (12%) 0 (0%) ns
Left ventricular hypertrophy (n (%)) 25 (74%) 15 (68%) ns
Left ventricular Diastolic Volume (ml)110 ± 32 124 ± 33 ns
Ejection Fraction (%) 60 ± 75 4 ± 13 0.0216
Mitral stenosis (n (%)) 1 (3%) 1 (5%) ns
Mitral incompetence (n (%)) 27 (79%) 22 (100%) 0.02
Aortic stenosis (n (%)) 1 (3%) 3 (14%) ns
Aortic incompetence (n (%)) 17 (50%) 15 (68%) ns
In the whole population multiple logistic regression
analysis showed an independent association between PHT
anddialysis vintage(Odds Ratio 1.022 (95% CI1.002–1.041)
(P = .0297)) and diastolic blood pressure (Odds Ratio 0.861
(95% CI 0.766–0.967) (P = .0116); R2 = 0.328).
5. Discussion
This is a cross-sectional study investigating a small number
of dialysis patients dealing with a underconsidered clinical
problem. Yigla et al. [2] demonstrated that patients with
PHT evaluated by echocardiography at the beginning of
HD treatment, and with PHT developing soon after HD
initiation, had shorter survival than their counterparts with-
out PHT. The mechanisms involved in PHT development
are still under investigation, but it has been reported that
HD patients with PHT show a signiﬁcantly higher cardiac
output than HD patients with normal PAP [3, 4]. It has been
suggested that some factors, such as the size or the location
of AVF, are involved in the mechanism that increases PAP.
On the contrary Tarrass et al. [8] did not ﬁnd any diﬀerence
in cardiac output between patients with and without PHT,
andtheeﬀectofAVFlocationwasnotstatisticallysigniﬁcant.
Beigi et al. [9]r e p o r t e dap o s i t i v ec o r r e l a t i o nb e t w e e n
mean ﬁstula ﬂow and PAP and, as well as in our study,
an inverse correlation between PAP and ejection fraction.
Unfortunately we did not measured ﬁstula ﬂow, therefore we
could not add anything regarding this relationship. However
we conﬁrm the strong reverse relationship between PAP and
ejection fraction. It has been reported that PHT improved
after successful kidney transplantation, as well as after short
AVF compression, indicating that both ESRD and AVF
contribute to its pathogenesis [5]. In our patients those
treated with HD had higher frequency of PHT than those on
PD. Moreover factors associated to PHT in subjects treated
with HD and PD seems to be diﬀerent, probably reﬂecting
ad i ﬀerent degree of damage of the cardiovascular system
during the history of the renal replacement treatment. To
the best of our knowledge this is the ﬁrst study suggesting
that PHT interpretation needs to be individualized based
on renal replacement therapy, suggestion reinforced by the
higher interdialytic weight gain in patients with PHT than in
thosewithnormalPAPandthepositive relationshipbetween
PAP and diastolic left ventricular volume. In agreement with
our ﬁnding Issa el al. [10] reported that time on dialysis was
thestrongestcorrelateofanelevatedrightventricularsystolic
pressure. The same authors stated that right ventricular
systolic pressure greater than 50mmHg was associated with
signiﬁcant reduced posttransplant survival [10]. On the
other hand Nakhoul et al. [5] demonstrated that reduced
nitric oxide production could increase PAP, PHT among HD
patients who underwent successful kidney transplantation
reversed, even if their AVF remained patent.
Other risk factors for PHT have been identiﬁed. Harp et
al. [11] in a retrospective study suggested that age was the
only risk factor, since each year of age increased the odds
of having PHT by 3%. Hyperparathyroidism, by causing
precipitation of calcium in many tissues, could play a role
in the development of PHT secondary to pulmonary artery
calciﬁcations. This notion is supported by an experimental
study in a dog model of ESRD [12]: animals with increased
PTH activity and lung calcium content had higher PAP
values than the dogs which underwent parathyroidectomy,
thus suggesting a link between PAP and hyperparathy-
roidism. On the contrary Amin et al. [13] did not conﬁrm
these ﬁndings in a group of ESRD on regular HD. In our
patients age, calcium, phosphate, PTH concentrations and
history of parathyroidectomy revealed no diﬀerence between
those with and without PHT. In a recent study Havlucu
et al. [14] evaluated 23 predialysis and 25 HD patients,4 International Journal of Nephrology
those with elevated PAP had increased PTH levels, cardiac
output values and chronic renal failure duration; AVF ﬂow
and duration were positively and residual urine volume
negatively correlated with PAP.
Kumbar et al. [15] reported, in 36 PD patients, that those
with PHT had lower ejection fraction, higher prevalence
of global hypokinesia and dilated left ventricular chamber
than patients without PHT. In the same way our ﬁndings
indicate that low cardiac performance is related to PHT in
PD subjects. Moreover in agreement with Yigla et al. [2]w e
found a higher prevalence of valvular damage in subjects
with PHT, however the diﬀerence was statistically signiﬁcant
only for aortic incompetence in the PD group.
The relationship between PHT and diastolic BP should
be interpreted in the same way, considering low diastolic
BP as an indirect index of arterial stiﬀness. PHT was more
frequent in HD than in PD, however this could be a bias
due to the fact that in the patients referred to our hospital,
PD subjects are usually healthier subjects than HD ones. The
latter are older than the former, and the presence of AVF in
HD but not in PD patients was bound to determine diﬀerent
(and worse) hemodynamic conditions.
Inconclusionour-cross-sectionalandretrospectivestudy
conﬁrms that PHT is a frequent condition in the uraemic
population, especially in aged patients with poor cardiovas-
cular conditions. Hence, PHT could complicate the clinical
picture of dialysis patients. On the other hand, our ﬁndings
indicate that PAP evaluation could be an useful parameter
for cardiovascular risk stratiﬁcation of uraemic patients that
needs to be interpreted based on patient history.
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